Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 31% on Thursday . The company traded as high as C$0.23 and last traded at C$0.19. 479,687 shares traded hands during mid-day trading, a decline of 9% from the average session volume of 525,136 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Up 31.0 %
The firm has a market capitalization of C$27.69 million, a P/E ratio of -5.54 and a beta of 0.20. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The firm has a 50 day moving average of C$0.20 and a 200-day moving average of C$0.12.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Are Penny Stocks a Good Fit for Your Portfolio?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
